DEVELOPMENTAL FUNDS

发展基金 要求提供470 000美元的发展资金，以支持HICCC试点项目倡议，以促进 翻译研究(32万美元)和评级在20位以上的杰出癌症项目 NIH研究部分的百分位数(150,000美元)。SLT于2007年实施了这些中心倡议。 在过去的供资期间，由于预算原因，CCSG发展基金每年仅限于147,806美元 最后一场比赛后的限制。在2005年3月任命中心主任之后，它 决定在该中心的研究计划完成之前，不会授予这一类别的资金 重组和中心成员资格的审查和批准。在提交本文件时，累积的 总额为591,224美元，已结转到2007年7月至2008年6月的免费延长期，用于 支持特定计划的试点项目。 在当前项目期间通过试点项目机制促进新的研究举措， HICCC利用总计170万美元的慈善资金，资助了HICCC的31个现任或前任成员。年度项目 一至两年的资金为35,000至50,000美元。Richard Baer，博士，Basic副主任 研究，监督该中心的试点项目倡议。他负责组织和选择广告 特别委员会成员根据资助机会的主题并确保严格 使用美国国立卫生研究院评分系统的科学审查。 在项目期间由慈善基金支持的选定试点项目包括： 有丝分裂中肿瘤抑制基因ARC的特征，Y.MAO(CGE) 结果：张军，艾哈迈德，S，毛勇，(2007)BubRland APC/EB1合作维持中期 染色体比对。J细胞生物学178：773-784。 乳腺癌基因组去甲基化的机制和后果 结果：NIH R01拨款基于规划阶段的试点数据。 小鼠乳腺中的干细胞和肿瘤干细胞，艾夫斯莱迪斯(BC) 结果：初步数据是2007年5月同一标题下“工作研究”的基础 哥伦比亚科技风险投资公司和默克。 T-ALL致癌途径剖析：逆转录病毒诱变与人T淋巴细胞白血病， A Ferrando(LDM) 结果：两份手稿正在准备中 螺旋环状螺旋转录因子在肿瘤细胞分化和增殖中的作用 结果：NIH/NCI R01CA85628 Id2在细胞周期调节和癌症$23万/年，8/1/2006- 7/31/2011 干细胞与表皮肿瘤的发生 结果：皮肤病基金会拨款，表皮干细胞作为皮肤肿瘤的靶点 $55,000/年，7/1/2006-6/30/2007 Id2蛋白在胶质瘤血管生成中的作用 结果：Lasorella A.，Stegmuller J.，Guardavaccaro D.，Liu G.，Carro M.S.，Rothschild G.，De la Torre- Ubieta L.，Pagano M.，Bonni A.，Lavarone A.，后期促进复合体对Id2的降解 将细胞周期退出和轴突生长结合起来。自然，422：471-474,2006 在项目期间收到试点项目资金的其他HICCC成员包括： J.Baer，K.Crew J.Gautier，D Hershman和K Joseph，(BC)；A Joe和I B Weinstein，(PCD)；MB Terry 和T Liu(CE)、W.Gu(CSN和BC)和J Kandel(PC)。 2007年，HICCC的高级领导团队就以下筹资机制达成一致，以促进内部和 方案间翻译研究： HICCC特定计划试点(PROSPE)基金，以刺激方案内翻译研究 首创精神。七个研究计划和发展中的神经肿瘤学计划中的每一个都被分配给 70000美元，用于在竞争的基础上资助一个与以下翻译目标具有战略相关性的试点项目 这个项目。资助机会已经公布，获奖者将于10月中旬选出。 ？HICCC方案间(InterPro)试点项目基金，以促进方案间翻译 研究计划。HICCC将为每个项目分配40,000美元，以在竞争基础上资助一个试点项目 涉及两个项目的PI的项目，优先考虑涉及以下项目的项目 两个截然不同的领域，即基础科学、特定疾病科学或人口科学。机构和慈善基金 将支持方案间协调中心的方案间试点项目倡议。融资机会一直是 公布的获奖者将于10月中旬选出 ？2007年夏天，HICCC发起了桥梁奖(BrAwa)，以支持 被美国国立卫生研究院研究部门评为首次申请或 有竞争力的更新，但由于预算限制没有得到资助。HICCC过渡奖将 在竞争的基础上，每年为两个75000美元的项目提供资金。关于这一融资机会的通知已经 已宣布，资金将于2007年12月发放。

DEVELOPMENTAL FUNDS Developmental funds, $470,000, are requested to support HICCC pilot project initiatives that foster translational research, ($320,000) and cancer projects of outstanding merit that were rated above the 20th percentile by an NIH study section ($150,000). These Center initiatives were implemented by the SLT in 2007. Over the past funding period CCSG Development funds were limited to $147,806 per year due to budgetary constraints following the last competition. Following the appointment of the Center Director in March 2005, it was decided that funds in this category would not be awarded until the Center's research programs were reorganized and Center membership reviewed and approved. At the time of this submission, the accumulated total, $591,224, has been carried over to the no-cost extension period, July 2007 - June 2008, to be used in support of program-specific pilot projects. To promote novel research initiatives through the pilot project mechanism during the current project period, HICCC utilized philanthropic funds totaling $1.7M to fund 31 current or former HICCC members. Annual project funding was $35,000 to $50,000 for one to two years. Richard Baer, PhD, Associate Director for Basic Research, oversees the Center's pilot project initiatives. He is responsible for organizing and selecting the ad hoc committee members based on the subject matter of the funding opportunity and ensuring rigorous scientific review using the NIH scoring system. Selected pilot projects supported by philanthropic funds during the project period include: ¿ Characterization of the tumor suppressor ARC in mitosis, Y. Mao (CGE) Outcome: Zhang, J., Ahmad, S., Mao, Y., (2007) BubRland APC/EB1 cooperate to maintain metaphase chromosome alignment. J Cell Biol 178: 773-784. ¿ Mechanisms and consequences of genome demethylation in mammary carcinoma, T. Bestor (CGE) Outcome: NIH R01 grant based on pilot data in planning stages. ¿ Stem cells and cancer stem cells in mouse mammary glands, A Efstratiadis (BC) Outcome: Preliminary data was the basis for a May 2007 "Work Study" under the same title between Columbia Science & Technology Ventures and Merck. ¿ Dissecting oncogenic pathways in T-ALL: retroviral mutagenesis and human T-cell lymphoblastic leukemia, A Ferrando (LDM) Outcome: two manuscripts in preparation ¿ Helix loop helix transcription factors in differentiation and proliferation of tumor cells, A lavarone (CSN) Outcome: NIH/NCI R01CA85628 Id2 in cell cycle regulation and cancer $230,000/year, 8/1/2006- 7/31/2011 ¿ Stem cells and the genesis of epidermal tumors, D Owens (CGE) Outcome: Dermatology Foundation grant, Epiderma stem cells as targets for cutaneous neoplasia $55,000/year, 7/1/2006-6/30/2007 ¿ Id2 protein in glioma tumor angiogenesis, A Lasorella (CSN) Outcome: Lasorella A., Stegmuller J., Guardavaccaro D., Liu G., Carro M.S., Rothschild G., de la Torre- Ubieta L., Pagano M., Bonni A., lavarone A., Degradation of Id2 by the anaphase promoting complex couples cell cycle exit and axonal growth. Nature, 422:471-474, 2006 Other HICCC members who received pilot project funds during the project period include: R. Baer, K. Crew J. Gautier, D Hershman, and K Joseph, (BC); A Joe and I B Weinstein, (PCD); and MB Terry and T Liu (CE), W. Gu (CSN and BC), and J Kandel (PC). In 2007, the HICCC's senior leadership team agreed on the following funding mechanisms to promote intraand inter-programmatic translational research: HICCC Program-specific Pilot (PROspe) Fund to stimulate intra-programmatic translational research initiatives. Each of the seven research programs and the developing Neuro-oncology program are assigned $70,000 to fund, on a competitive basis, a pilot project of strategic relevance to the translational goals of the program. Funding opportunities have been announced and awardees will be selected by mid October. ¿ HICCC Inter-programmatic (InterPro) Pilot Project Fund to stimulate inter-programmatic translational research initiatives. The HICCC will assign to each program $40,000 to fund, on a competitive basis, a pilot project that involves Pis from two programs, with priority given to those projects involving programs from two distinct areas, i.e., basic, disease-specific, or population science. Institutional and philanthropic funds will support the HICCC inter-programmatic pilot project initiative. Funding opportunities have been announced and awardees will be selected by mid-October ¿ In the summer of 2007, the HICCC initiated the Bridging Award (BrAwa) to support cancer projects of outstanding merit that were rated above the 20th percentile by an NIH study section as a first application or competitive renewal but were not funded due to budgetary restrictions. The HICCC Bridging Award will fund annually, on a competitive basis, two $75,000 projects. Notices of this funding opportunity have been announced and funding will be awarded in December 2007.